Skip to content

Tango Therapeutics

US · TNGX #2322 by market cap Listed 1970
21.73 -0.98 -4.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:41

Price chart

Pre-market 22.01 -3.08%
After-hours 22.00 +1.24%
32.9019.6521.732026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TNGX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +68.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 28.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -178.4% Better than 6%
Net margin -162.9% Better than 6%
Return on equity -37.2% Better than 11%
Return on invested capital -34.8% Better than 9%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -9.0% Better than 53%
6-month return 7.4% Better than 68%
12-month return (ex latest month) 178.5% Better than 99%
Distance below 52-week high 36.8% Better than 32%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 16.3x Better than 97%
Debt to assets 8.4% Better than 73%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 124.0% Better than 87%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -14.78%
1M -13.94%
3M -7.57%
6M +3.08%
YTD +145.26%
1Y +144.16%
3Y +185.55%
5Y +81.54%

Key statistics

Price & volume

Prev close
22.71
Open
22.11
Day range
21.63 - 23.05
Avg price
21.98
Volume
1.74M
Turnover
38.26M
Amplitude
6.25%
52-week range
8.30 - 34.39

Valuation

P/E
-24.98
P/E (TTM)
-15.75
P/B
3.76
EPS
-0.87
Net profit
-147.43M
Net assets
980.13M

Share structure

Market cap
3.68B
Float cap
3.11B
Shares out
169.46M
Float shares
143.08M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 51% of range
8.30 34.39

36.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+34.66M net over the window

Short interest

Shares short
48.24M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Tango Therapeutics (TNGX)?

Tango Therapeutics last traded at 21.73. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Tango Therapeutics's market cap?

About 3.68B.

What is the P/E ratio of Tango Therapeutics?

The trailing twelve-month P/E is -15.75. The Valuation tab shows it against the stock's own five-year range.

Does Tango Therapeutics pay a dividend?

Tango Therapeutics does not currently pay a regular dividend.

Is Tango Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 48.67, which implies 124.0% upside from the current price. This is not investment advice.

What is Tango Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Tango Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.

Tango Therapeutics discussion 0 comments

Add a comment